SAVOXEPINE - STRIATAL DOPAMINE-D2-RECEPTOR OCCUPANCY IN HUMAN VOLUNTEERS MEASURED USING POSITRON EMISSION TOMOGRAPHY (PET)

被引:10
|
作者
LEENDERS, KL
ANTONINI, A
THOMANN, R
LOCHER, JT
MAITRE, L
GEREBTZOFF, A
BEER, HF
AMETAMEY, S
WEINREICH, R
GUT, A
GNIRSS, F
OFNER, S
SCHILLING, W
WALDMEIER, PC
机构
[1] CIBA GEIGY AG,DEPT FORSCH & ENTWICKLUNG,DIV PHARMA,CH-4002 BASEL,SWITZERLAND
[2] PAUL SCHERRER INST,PET PROGRAM,VILLIGEN,SWITZERLAND
[3] KANTONALE PSYCHIAT KLIN KONIGSFELDEN,BRUGG,SWITZERLAND
[4] KANTONSSPITAL AARAU,NUKL MED ABT,AARAU,SWITZERLAND
[5] PAUL SCHERRER INST,RADIOPHARM ABT,VILLIGEN,SWITZERLAND
关键词
SAVOXEPINE; NEUROLEPTIC DRUG; DOPAMINE-D2-RECEPTOR ANTAGONIST; POSITRON EMISSION TOMOGRAPHY; STRIATAL RECEPTOR BINDING; HEALTHY VOLUNTEERS;
D O I
10.1007/BF00315470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The extent and duration of striatal dopamine-D2 receptor occupancy by savoxepine in humans has been studied using positron emission tomography with [C-11]-raclopride, in order to investigate why the anticipated favourable ratio between its extrapyramidal and antipsychotic effects was not achieved in practice. After 0.25 mg savoxepine, striatal D2 receptor occupancy peaked at 50-60% after 24-36 h and disappeared within 6 days. After doses of 0.1 mg to 0.5 mg, D2 receptor occupancy in the putamen and caudate nucleus increased from 20 to 70% 3-7 h after administration and amounted to 40 to 75% at the peak time (20-29 h). This suggests that cumulative D2 receptor blockade would occur if equal or increasing doses of savoxepine were given repeatedly. Extrapyramidal adverse-effects would be likely to occur under such circumstances. An adequate test of the theory that preference for hippocampal dopamine D2 receptors with afford a good therapeutic ratio requires an alternative dosing regimen.
引用
收藏
页码:135 / 140
页数:6
相关论文
共 50 条
  • [31] Increased dopamine D2-receptor availability in patients with Restless Legs Syndrome as measured with Positron Emission Tomography
    Cervenka, S
    Pålhagen, SE
    Comley, RA
    Panagiotidis, G
    Matthews, JC
    Lai, RY
    Halldin, C
    Farde, L
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S47 - S47
  • [32] Effects of lorazepam administration on striatal dopamine D-2 receptor binding characteristics in man - a positron emission tomography study
    Hietala, J
    Kuoppamaki, M
    Nagren, K
    Lehikoinen, P
    Syvalahti, E
    PSYCHOPHARMACOLOGY, 1997, 132 (04) : 361 - 365
  • [33] DOPAMINE RECEPTOR ALTERATIONS IN ASYMMETRICAL AND SYMMETRICAL PARKINSONISM MEASURED BY POSITRON EMISSION TOMOGRAPHY
    FROST, JJ
    UHL, GE
    WONG, DF
    PREZIOSI, TJ
    DANNALS, RF
    RAVERT, HT
    WAGNER, HN
    ANNALS OF NEUROLOGY, 1984, 16 (01) : 128 - 129
  • [34] Increased dopamine D2-receptor availability in patients with restless legs syndrome as measured with positron emission tomography
    Cervenka, S
    Pålhagen, SE
    Comley, RA
    Panagiotidis, G
    Matthews, JC
    Lai, RY
    Halldin, C
    Farde, L
    ANNALS OF NEUROLOGY, 2005, 58 : S22 - S22
  • [35] Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man – a positron emission tomography study
    J. Hietala
    Mikko Kuoppamäki
    Kjell Någren
    Pertti Lehikoinen
    Erkka Syvälahti
    Psychopharmacology, 1997, 132 : 361 - 365
  • [36] EFFECTS OF CENTRAL CHOLINERGIC BLOCKADE ON STRIATAL DOPAMINE RELEASE MEASURED WITH POSITRON EMISSION TOMOGRAPHY IN NORMAL HUMAN-SUBJECTS
    DEWEY, SL
    SMITH, GS
    LOGAN, J
    BRODIE, JD
    SIMKOWITZ, P
    MACGREGOR, RR
    FOWLER, JS
    VOLKOW, ND
    WOLF, AP
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) : 11816 - 11820
  • [37] D1 DOPAMINE RECEPTOR-BINDING IN MOOD DISORDERS MEASURED BY POSITRON EMISSION TOMOGRAPHY
    SUHARA, T
    NAKAYAMA, K
    INOUE, O
    FUKUDA, H
    SHIMIZU, M
    MORI, A
    TATENO, Y
    PSYCHOPHARMACOLOGY, 1992, 106 (01) : 14 - 18
  • [38] BRAIN GLUCOSE-METABOLISM AND STRIATAL DOPAMINE RECEPTOR DENSITY IN SUBJECTS GENETICALLY AT RISK FOR HUNTINGTONS-DISEASE (HD) MEASURED WITH POSITRON EMISSION TOMOGRAPHY (PET)
    ANTONINI, A
    WEINDL, A
    LEENDERS, KL
    NEUROLOGY, 1993, 43 (04) : A335 - A335
  • [39] DOPAMINE D2 RECEPTORS IN NORMAL HUMAN BRAIN - EFFECT OF AGE MEASURED BY POSITRON EMISSION TOMOGRAPHY (PET) AND [C-11] RACLOPRIDE
    ANTONINI, A
    LEENDERS, KL
    ALZHEIMERS DISEASE: AMYLOID PRECUSOR PROTEINS, SIGNAL TRANSDUCTION, AND NEURONAL TRANSPLANTATION, 1993, 695 : 81 - 85
  • [40] INVIVO QUANTIFICATION OF ABSOLUTE D2 DOPAMINE RECEPTOR DENSITY USING POSITRON EMISSION TOMOGRAPHY - PRELIMINARY HUMAN STUDIES
    WONG, DF
    GJEDDE, A
    WAGNER, HN
    DANNALS, RF
    TUNE, L
    TAMMINGA, C
    OTUAMA, L
    WILLIAMS, J
    GOLDBERG, DS
    LINKS, J
    JOURNAL OF NUCLEAR MEDICINE, 1986, 27 (06) : 954 - 955